By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



29 Emmons Drive
Suite C-10
Princeton  New Jersey  08540  U.S.A.
Phone: 609-538-8200 Fax: 609-452-6467


Company News
Soligenix (SNGX) Receives $617,000 In Non-Dilutive Financing From New Jersey's Technology Business Tax Certificate Transfer Program 12/11/2014 7:19:54 AM
Soligenix (SNGX) Appoints Oreola Donini, PhD, As Chief Scientific Officer 12/10/2014 7:34:29 AM
Soligenix (SNGX) Announces Formation Of Cutaneous T-Cell Lymphoma Medical Advisory Board 11/17/2014 11:51:57 AM
Soligenix (SNGX) Reports Third Quarter 2014 Financial Results, Highlighted With The Acquisition Of SGX301, Synthetic Hypericin, For The Treatment Of Cutaneous T-Cell Lymphoma 11/10/2014 8:47:54 AM
Vista Partners Updates Coverage On Soligenix (SNGX). (Ticker: SNGX); Revises Price Target Higher From $5.50 To $7.00 9/26/2014 2:43:43 PM
Soligenix (SNGX) Appoints Rasappa Arumugham, PhD, As Vice President Of Biopharmaceutical Development 9/23/2014 8:14:13 AM
Soligenix (SNGX) Awarded National Institute of Allergy And Infectious Diseases (NIAID) Contract Valued Up To $24.7 Million 9/19/2014 6:25:08 AM
Soligenix (SNGX) Announces FDA Clearance Of Phase 3 Clinical Protocol Of SGX301 In Cutaneous T-Cell Lymphoma 9/17/2014 9:19:52 AM
Soligenix (SNGX) Announces Issuance Of US Patent for ThermoVax™ Technology 9/9/2014 7:59:13 AM
Soligenix (SNGX) To Present At The 16th Annual Rodman & Renshaw Global Investment Conference In New York City 9/8/2014 8:44:09 AM